ArticleStem cells translational medicine2020
Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder.
Article in Stem cells translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Bibliometric study of neuroinflammation in autism spectrum disorder.Frontiers in psychiatry · 2023Pooled it
- Stem Cell Therapy in the Treatment of Patients With Autism Spectrum Disorder: a Systematic Review and Meta-analysis.Stem cell reviews and reports · 2022Pooled it
- Efficacy and safety of allogeneic umbilical cord blood mononuclear cells therapy in children with autism spectrum disorder and immune dysregulation: a single-center, double-blinded, randomized, placebo-controlled trial.Stem cell research & therapy · 2026Trial
- Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial.EBioMedicine · 2026Trial
- A Randomized, Placebo-Controlled, Phase II Trial of Intravenous Allogeneic Non-HLA Matched, Unrelated Donor, Cord Blood Infusion for Ischemic Stroke.Stem cells translational medicine · 2024Trial
- A Pilot Phase I Trial of Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells in Neonates With Hypoxic-Ischemic Encephalopathy.Stem cells translational medicine · 2023Trial
- Motor function and safety after allogeneic cord blood and cord tissue-derived mesenchymal stromal cells in cerebral palsy: An open-label, randomized trial.Developmental medicine and child neurology · 2022Trial
- HPSC-derived mesenchymal stromal cells ameliorate murine autistic-like phenotypes through activating oxytocinergic neurons.Science advances · 2026Article
- Cord-Derived Stem Cells for Pediatric Autism Spectrum Disorder: Biological Rationale and Source-Specific Trial Design.International journal of molecular sciences · 2026Review
- Compartment-specific eccDNA patterns reveal senescence associated biomarkers in hUC-MSCs.Scientific reports · 2026Article
- Mesenchymal stromal/stem cells for neurological disorders in humans: an evidence-mapped clinical review.Frontiers in cellular neuroscience · 2026Review
- Stem Cell Therapy and Models for Autism Spectrum Disorder: Insights and Research.Current neuropharmacology · 2026Review
- Dual-target hUCMSCs/EVs therapy for autism spectrum disorder: remodeling gut microbiota and modulating neuroimmune crosstalk in a valproic acid-induced C57BL/6 mice model.Stem cell research & therapy · 2025Article
- Mesenchymal stem cells in neurological disorders: Insights from clinical trials.Regenerative therapy · 2025Review
- Review
- Mesenchymal Stromal Cell Treatment Alleviates Autism Spectrum Disorder Symptoms: A Case Report.Cureus · 2025Article
- Optimization of Culture Media for Human Umbilical Cord-Derived Mesenchymal Stem Cell Production.Stem cells international · 2025Article
- Intrathecal injection of bone marrow concentrate in children with autism spectrum disorder: a retrospective chart analysis.Frontiers in medicine · 2025Article
- Convergence of Neuroinflammation, Microbiota, and Parkinson's Disease: Therapeutic Insights and Prospects.International journal of molecular sciences · 2024Review
- Mesenchymal Stem Cell-Induced Neuroprotection in Pediatric Neurological Diseases: Recent Update of Underlying Mechanisms and Clinical Utility.Applied biochemistry and biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Ongoing neuroinflammation may contribute to symptoms of autism spectrum disorder (ASD) in at least a portion of affected individuals. Mesenchymal stromal cells (MSCs) have demonstrated the capacity to modulate neuroinflammation, but safety and feasibility of MSC administration in children with ASD have not been well established. In this open-label, phase I study, 12 children with ASD between 4 and 9 years of age were treated with intravenous (IV) infusions of human cord tissue mesenchymal stromal cells (hCT-MSCs), a third-party MSC product manufactured from unrelated donor umbilical cord tissue. Children received one, two, or three doses of 2 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.